In the context of T2DM, the development of such multi-target drugs has recently been reviewed [10,11,12] to highlight agonists acting on incretin, glucagon systems, and peroxisome proliferation activated receptors, just to mention a few. Here, GCG is linked to type 2 diabetes mellitus.